Customize your JAMA Network experience by selecting one or more topics from the list below.
Telaprevir, combined with pegylated interferon alfa and ribavirin, is an efficacious approach to treat hepatitis C virus infection. A morbilliform eruption associated with telaprevir is a common adverse effect experienced by patients. Current guidelines mandate telaprevir discontinuation in any patient with a severe, progressive, or unresponsive cutaneous eruption.
Eight patients with a grade 3 (severe) widespread morbilliform eruption associated with telaprevir were referred to dermatology for evaluation and treatment. Each patient received a combination of antihistamines, topical corticosteroids, and thick emollient creams, rendering their eruption tolerable for the duration of treatment. No patients had evidence of a systemic or life-threatening drug reaction, developed a systemic drug eruption, or had to prematurely stop triple therapy secondary to a cutaneous eruption.
Conclusions and Relevance
Patients with an uncomplicated grade 3 (severe) widespread morbilliform eruption associated with telaprevir may be able to continue triple therapy with close monitoring and dermatologic consultation. Given our findings, we propose an additional clinical classification of the telaprevir-associated eruption to better reflect the dermatologic classification of drug eruptions.
Strazzula L, Pratt DS, Zardas J, Chung RT, Thiim M, Kroshinsky D. Widespread Morbilliform Eruption Associated With Telaprevir: Use of Dermatologic Consultation to Increase Tolerability. JAMA Dermatol. 2014;150(7):756–759. doi:10.1001/jamadermatol.2013.9938
Create a personal account or sign in to: